Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 383-385

  Rakofsky, Jeffrey Jay ^a   Dunlop, Boadie W ^a   Beyer, John L ^b   Oliver, Alison M ^a   Mansson, Erika E ^a   Sancheti, Madhur T ^a   Harvey, Philip D ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; OPIATE; PLACEBO; QUETIAPINE; VALPROIC ACID; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; COGNITION; DEPENDENT PERSONALITY DISORDER; DRUG EFFECT; EUTHYMIC BIPOLAR DISORDER; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LETTER; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; PRIORITY JOURNAL; SCREENING; SEDATION; SUBSTANCE ABUSE; VERBAL MEMORY; WILCOXON SIGNED RANKS TEST; YOUNG MANIA RATING SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COGNITION; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84900509494     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000078     Document Type: Letter

References (10)

1. Torrent C, Martinez-Arán A, Daban C, et al. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry. 2011;52: 613-622.
2. Kozicky JM, Torres IJ, Bond DJ, et al. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. Int Clin Psychopharmacol. 2012;27:91-99.
3. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33: 2303-2312.
4. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33; quiz 34-57.
5. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
6. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
7. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
8. Fox KH, Burdick KE, Lombardo I, et al. Cognitive impairment in patients with bipolar disorder. Psychiatric Times. 2009;12:1-2.
9. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33: 1364-1372.
10. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198-203.